Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significant Differences in Capsid Properties and Potency Between Adeno-Associated Virus Vectors Produced in Sf9 and HEK293 Cells

19 Aug 2023

Abstract excerpt

For successful vector-based gene therapy manufacturing, the selected adeno-associated virus (AAV) vector production system must produce vector at sufficient scale. However, concerns have arisen regarding the quality of vector produced using different systems. In this study, we compared AAV serotypes 1, 8, and 9 produced by two different systems (Sf9/baculovirus and HEK293/transfection) and purified by two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37597192
DOI: 10.1089/hum.2022.116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significant Differences in Capsid Properties and Potency Between Adeno-Associated Virus Vectors Produced in Sf9 and HEK293 CellsPMID 37597192Read ↗

Methods Matter -- Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct VectorsSemantic proximity Read ↗

Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing.Semantic proximity Read ↗

Manufacturing of recombinant adeno‐associated viruses using mammalian expression platformsSemantic proximity Read ↗

Production, Processing, and Characterization of Synthetic AAV Gene Therapy VectorsSemantic proximity Read ↗

A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platformSemantic proximity Read ↗

Manufacturing of recombinant adeno-associated viral vectors for clinical trialsSemantic proximity Read ↗

Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at ScaleSemantic proximity Read ↗

Removal of Empty Capsids from High-Dose Adeno-Associated Virus 9 Gene TherapiesSemantic proximity Read ↗

AAV- based vector improvements unrelated to capsid protein modificationSemantic proximity Read ↗

Recent Advances in the Analysis Full/Empty Capsid Ratio and Genome Integrity of Adeno-associated Virus (AAV) Gene Delivery VectorsSemantic proximity Read ↗

A simplified purification protocol for recombinant adeno-associated virus vectorsSemantic proximity Read ↗

Unravelling the essential elements for recombinant adeno-associated virus (rAAV) production in animal cell-based platformsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.